AIM: To assess the effects of neoadjuvant chemoradiotherapy (CRT) on the presence of extracapsular lymph node involvement (LNI) and its prognostic value in patients with resected esophageal cancer. METHODS: Two hundred and ninety-eight patients with advanced esophageal cancer underwent esophagectomy between 1997 and 2006. One hundred and ninety patients (63.8%) were treated with neoadjuvant CRT prior to resection. A total of 986 metastatic LNs were examined. Survival of the patients was analyzed according to intra- and extra-capsular LNI. RESULTS: Five-year survival rate was 22.5% for the entire patient population. Patients with extracapsular LNI had a 5-year survival rate of 16.7%, which was comparable to the 15.8% in patients with infiltrated nodes of the celiac trunk (pM1lymph). In contrast to patients treated with surgery alone, neoadjuvant therapy resulted in significantly (P = 0.001) more patients with pN0/M0 (51.6% vs 25.0%). In 17.6% of the patients with surgery alone vs 16.8% with neoadjuvant CRT, extracapsular LNI was detected. Neoadjuvant therapy does not reduce the occurrence of extracapsular LNI. CONCLUSION: Extracapsular LNI is an independent negative prognostic factor not influenced by neoadjuvant CRT. In a revised staging system for esophageal cancer, extracapsular LNI should be considered.
AIM: To assess the effects of neoadjuvant chemoradiotherapy (CRT) on the presence of extracapsular lymph node involvement (LNI) and its prognostic value in patients with resected esophageal cancer. METHODS: Two hundred and ninety-eight patients with advanced esophageal cancer underwent esophagectomy between 1997 and 2006. One hundred and ninety patients (63.8%) were treated with neoadjuvant CRT prior to resection. A total of 986 metastatic LNs were examined. Survival of the patients was analyzed according to intra- and extra-capsular LNI. RESULTS: Five-year survival rate was 22.5% for the entire patient population. Patients with extracapsular LNI had a 5-year survival rate of 16.7%, which was comparable to the 15.8% in patients with infiltrated nodes of the celiac trunk (pM1lymph). In contrast to patients treated with surgery alone, neoadjuvant therapy resulted in significantly (P = 0.001) more patients with pN0/M0 (51.6% vs 25.0%). In 17.6% of the patients with surgery alone vs 16.8% with neoadjuvant CRT, extracapsular LNI was detected. Neoadjuvant therapy does not reduce the occurrence of extracapsular LNI. CONCLUSION: Extracapsular LNI is an independent negative prognostic factor not influenced by neoadjuvant CRT. In a revised staging system for esophageal cancer, extracapsular LNI should be considered.
Authors: J Wind; S M Lagarde; F J W Ten Kate; D T Ubbink; W A Bemelman; J J B van Lanschot Journal: Eur J Surg Oncol Date: 2006-12-15 Impact factor: 4.424
Authors: Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes Journal: Lancet Oncol Date: 2007-03 Impact factor: 41.316
Authors: Nabil P Rizk; Ennapadam Venkatraman; Manjit S Bains; Bernard Park; Raja Flores; Laura Tang; David H Ilson; Bruce D Minsky; Valerie W Rusch Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Matthew Wilson; Ernest L Rosato; Karen A Chojnacki; Inna Chervoneva; John C Kairys; Herbert E Cohn; Francis E Rosato; Adam C Berger Journal: J Surg Res Date: 2007-08-28 Impact factor: 2.192
Authors: Dean Bogoevski; Florian Onken; Alexandra Koenig; Jussuf T Kaifi; Paulus Schurr; Guido Sauter; Jakob R Izbicki; Emre F Yekebas Journal: Ann Surg Date: 2008-04 Impact factor: 12.969
Authors: Alexander J Greenstein; Virginia R Litle; Scott J Swanson; Celia M Divino; Stuart Packer; Juan P Wisnivesky Journal: J Am Coll Surg Date: 2007-11-12 Impact factor: 6.113
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245